411 related articles for article (PubMed ID: 38254110)
1. Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes.
Liu H; Tang L; Li Y; Xie W; Zhang L; Tang H; Xiao T; Yang H; Gu W; Wang H; Chen P
Mol Cancer; 2024 Jan; 23(1):20. PubMed ID: 38254110
[TBL] [Abstract][Full Text] [Related]
2. The immune escape mechanism of nasopharyngeal carcinoma.
Li X; Guo Y; Xiao M; Zhang W
FASEB J; 2023 Jul; 37(7):e23055. PubMed ID: 37358482
[TBL] [Abstract][Full Text] [Related]
3. Natural Variations in BRLF1 Promoter Contribute to the Elevated Reactivation Level of Epstein-Barr Virus in Endemic Areas of Nasopharyngeal Carcinoma.
Zhang JB; Huang SY; Wang TM; Dong SQ; He YQ; Zheng XH; Li XZ; Wang F; Jianbing M; Jia WH
EBioMedicine; 2018 Nov; 37():101-109. PubMed ID: 30420297
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus DNA seropositivity links distinct tumoral heterogeneity and immune landscape in nasopharyngeal carcinoma.
Li W; Lv S; Liu G; Lu N; Jiang Y; Liang H; Xia W; Xiang Y; Xie C; He J
Front Immunol; 2023; 14():1124066. PubMed ID: 36860875
[TBL] [Abstract][Full Text] [Related]
5. Targeting the crosstalk of epigenetic modifications and immune evasion in nasopharyngeal cancer.
Looi CK; Foong LC; Chung FF; Khoo AS; Loo EM; Leong CO; Mai CW
Cell Biol Toxicol; 2023 Dec; 39(6):2501-2526. PubMed ID: 37755585
[TBL] [Abstract][Full Text] [Related]
6. Updates on Epstein-Barr Virus (EBV)-Associated Nasopharyngeal Carcinoma: Emphasis on the Latent Gene Products of EBV.
Ahmed N; Abusalah MAHA; Farzand A; Absar M; Yusof NY; Rabaan AA; AlSaihati H; Alshengeti A; Alwarthan S; Alsuwailem HS; Alrumaih ZA; Alsayyah A; Yean CY
Medicina (Kaunas); 2022 Dec; 59(1):. PubMed ID: 36676626
[TBL] [Abstract][Full Text] [Related]
7. Multiplex Epstein-Barr virus BALF2 genotyping detects high-risk variants in plasma for population screening of nasopharyngeal carcinoma.
Miller JA; Sahoo MK; Yamamoto F; Huang C; Wang H; Zehnder JL; Le QT; Pinsky BA
Mol Cancer; 2022 Jul; 21(1):154. PubMed ID: 35902864
[TBL] [Abstract][Full Text] [Related]
8. Revealing the crosstalk between nasopharyngeal carcinoma and immune cells in the tumor microenvironment.
Jiang J; Ying H
J Exp Clin Cancer Res; 2022 Aug; 41(1):244. PubMed ID: 35964134
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapeutic approaches in nasopharyngeal carcinoma.
Chow JC; Ngan RK; Cheung KM; Cho WC
Expert Opin Biol Ther; 2019 Nov; 19(11):1165-1172. PubMed ID: 31361154
[No Abstract] [Full Text] [Related]
10. Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma.
Li W; Duan X; Chen X; Zhan M; Peng H; Meng Y; Li X; Li XY; Pang G; Dou X
Front Immunol; 2022; 13():1079515. PubMed ID: 36713430
[TBL] [Abstract][Full Text] [Related]
11. Emerging therapeutic targets for nasopharyngeal carcinoma: opportunities and challenges.
Baloche V; Ferrand FR; Makowska A; Even C; Kontny U; Busson P
Expert Opin Ther Targets; 2020 Jun; 24(6):545-558. PubMed ID: 32249657
[No Abstract] [Full Text] [Related]
12. Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect.
Siak PY; Heng WS; Teoh SSH; Lwin YY; Cheah SC
J Transl Med; 2023 Nov; 21(1):786. PubMed ID: 37932756
[TBL] [Abstract][Full Text] [Related]
13. Nasopharyngeal Carcinoma Progression: Accumulating Genomic Instability and Persistent Epstein-Barr Virus Infection.
Liu X; Deng Y; Huang Y; Ye J; Xie S; He Q; Chen Y; Lin Y; Liang R; Wei J; Li Y; Zhang J
Curr Oncol; 2022 Aug; 29(9):6035-6052. PubMed ID: 36135044
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of circulating Epstein-Barr virus DNA analysis for the management of nasopharyngeal carcinoma.
Fung SY; Lam JW; Chan KC
Chin Clin Oncol; 2016 Apr; 5(2):18. PubMed ID: 27121878
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr viral product-containing exosomes promote fibrosis and nasopharyngeal carcinoma progression through activation of YAP1/FAPα signaling in fibroblasts.
Lee PJ; Sui YH; Liu TT; Tsang NM; Huang CH; Lin TY; Chang KP; Liu SC
J Exp Clin Cancer Res; 2022 Aug; 41(1):254. PubMed ID: 35986369
[TBL] [Abstract][Full Text] [Related]
16. Five-year disease-free survival of Epstein-Barr virus-associated locoregionally advanced undifferentiated nasopharyngeal carcinoma patients treated with chemo-radiotherapy: a case report.
Wang N; Wang H; Jiang H; Bi Y; Zhao Y; He X; Cao F; Yuan Y
Ann Palliat Med; 2022 Mar; 11(3):1147-1152. PubMed ID: 35365045
[TBL] [Abstract][Full Text] [Related]
17. Epigenomic landscape study reveals molecular subtypes and EBV-associated regulatory epigenome reprogramming in nasopharyngeal carcinoma.
Ka-Yue Chow L; Lai-Shun Chung D; Tao L; Chan KF; Tung SY; Cheong Ngan RK; Ng WT; Wing-Mui Lee A; Yau CC; Lai-Wan Kwong D; Ho-Fun Lee V; Lam KO; Liu J; Chen H; Dai W; Lung ML
EBioMedicine; 2022 Dec; 86():104357. PubMed ID: 36371985
[TBL] [Abstract][Full Text] [Related]
18. Metabolic reprogramming in nasopharyngeal carcinoma: Mechanisms and therapeutic opportunities.
Liu Q; Bode AM; Chen X; Luo X
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):189023. PubMed ID: 37979733
[TBL] [Abstract][Full Text] [Related]
19. Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy.
Xu JY; Wei XL; Ren C; Zhang Y; Hu YF; Li JY; Chen JL; Wang YQ; Han F; Wang FH
JAMA Netw Open; 2022 Mar; 5(3):e220587. PubMed ID: 35230439
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr Virus Epithelial Cancers-A Comprehensive Understanding to Drive Novel Therapies.
Han S; Tay JK; Loh CJL; Chu AJM; Yeong JPS; Lim CM; Toh HC
Front Immunol; 2021; 12():734293. PubMed ID: 34956172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
